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Statins are some of the most widely used drugs worldwide, but one of their major side 35 
effects is myotoxicity. Using mouse myoblast (C2C12) and human alveolar rhabdomyosarcoma 36 
cell lines (RH30) in 2-dimensional (2D) and 3-dimensional (3D) culture, we investigated the 37 
mechanisms of simvastatin’s myotoxicity. We found that simvastatin significantly reduced cell 38 
viability in C2C12 cells compared to RH30 cells. However, simvastatin induced greater 39 
apoptosis in RH30 compared to C2C12 cells. Simvastatin-induced cell death is dependent on 40 
Geranylgeranyl pyrophosphate (GGPP) in C2C12 cells, while in RH30 cells it is dependent on 41 
both Farnesyl pyrophosphate (FPP) and GGPP. Simvastatin inhibited autophagy flux in both 42 
C2C12 and RH30 cells and inhibited lysosomal acidification in C2C12 cells, while autophagy 43 
inhibition with Bafilomycin-A1 increased simvastatin myotoxicity in both cell lines. Simvastatin 44 
induced more cell death in RH30 cells compared to C2C12 in 3D culture model with similar 45 
effects on autophagy flux as in 2D culture. Overall our results suggest that simvastatin-induced 46 
myotoxicity involves both apoptosis and autophagy, where autophagy serves a pro-survival role 47 
in both cell lines. The sensitivity to simvastatin myotoxicity is different in 2D versus 3D culture, 48 
demonstrating that the cellular microenvironment is a critical factor in regulating simvastatin-49 









The statin drugs (‘statins’) are competitive inhibitors of HMG-CoA (3-hydroxy-3-57 
methylgutarylcoenzyme A) reductase, and thus attenuate cholesterol and isoprenoid biosynthesis 58 
in the mevalonate (MA) pathway (Endo et al., 1977). They are used clinically as lipid-lowering 59 
drugs that prevent and treat cardiovascular diseases including atherosclerosis, coronary artery 60 
disease, and stroke (Grundy and Vega, 1985; Illingworth and Sexton, 1984; Tikkanen and 61 
Nikkila, 1987). The MA pathway is an essential contributor to mammalian cell homeostasis, as it 62 
is involved in the regulation of a multitude of cellular processes that require cholesterol and the 63 
isoprenoid intermediates (Cartocci et al., 2017; Hashemi et al., 2017). Cholesterol is the final 64 
sterol product of the MA cascade but several upstream isoprenoid metabolites including Farnesyl 65 
pyrophosphate (FPP) and Geranylgeranyl pyrophosphate (GGPP) are necessary for the 66 
prenylation of monomeric small GTPase proteins (e.g. Rho, Ras, Rac, Cdc42, Rab, Rap) 67 
(Hashemi et al., 2017; Sheikholeslami et al., 2019). These prenylated GTPases are critical cell 68 
signaling molecules involved in many basic cellular processes including proliferation, growth, 69 
migration, cytoskeletal dynamics, vesicular trafficking, barrier integrity, and smooth muscle 70 
contraction, to name a few. Thus, the MA pathway is tightly regulated to maintain these precise 71 
cellular functions under varied conditions in many cell types critical to health and disease (Jiao et 72 
al., 2017; Yeganeh et al., 2014). 73 
Statins are generally well-tolerated medications, however, there are side effects associated 74 
with these compounds which are dose-dependent. One of the most important and clinically 75 
relevant side effects is skeletal muscle myopathy which occurs in 1–5% of patients who take 76 
statins. Rarely, this can lead to lethal rhabdomyolysis if it is not diagnosed promptly (Ballantyne 77 
et al., 2003; Graham et al., 2004; Staffa et al., 2002; Thompson et al., 2003). According to recent 78 
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investigations, statin-related muscle disorders are potentially dependent on the inhibition of FPP 79 
and GGPP (Bhardwaj et al., 2013; Matzno et al., 1997). Treatment of C2C12 cells with GGPP 80 
can reverse the inhibitory effects of statins on myotube formation (Baba et al., 2008). In support 81 
of these findings, there is evidence that statin-induced muscle toxicity is connected to the 82 
inhibition of protein geranylgeranylation (Johnson et al., 2004), where prenylation of small 83 
GTPases is essential to their signaling function, including RAP GTPase. This reaction 84 
exclusively requires geranylgeranylation of RAP1A small Rho-GTPase protein, which is 85 
catalyzed by the prenyltransferases (Crick et al., 1997). Although these investigations have been 86 
illuminating regarding statin-induced muscle toxicity, the exact mechanisms underlying this 87 
phenomenon remain incompletely understood.  88 
Macroautophagy (hereafter listed as autophagy) is a multi step ‘‘self-eating’’ physiological 89 
process that regulates cellular response to stress (Amiri et al., 2019). Autophagy can be involved 90 
in both survival and death mechanisms based on the type of the cells and stimuli (Hombach-91 
Klonisch et al., 2018; Mokarram et al., 2017). Once it has been induced, tightly regulated 92 
sequential steps direct the formation of a bilayer vesicle called the autophagosome to consume 93 
cytoplasmic cargo (Klionsky et al., 2016; Mehrbod et al., 2019). This cargo is then ubiquitinated 94 
and recognized by autophagy receptors like p62. The cargo receptor later binds to the cargo and 95 
LC3-II, a component of the autophagosome membrane, which facilitates the isolation of the 96 
cargo and its delivery to lysosomes.  97 
Autophagy can be involved in regulation of programmed cell death I (apoptosis) under 98 
different scenarios: i) as a positive controller (autophagy increases apoptosis), ii)  as a negative 99 
controller (autophagy decreases apoptosis), or iii) parallel to apoptosis (autophagy does not 100 
change cellular apoptosis) (Ghavami et al., 2010a; Ghavami et al., 2010b; Ghavami et al., 2012a; 101 
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Ghavami et al., 2011; Ghavami et al., 2014; Ghavami et al., 2012b; Liu et al., 2017; Song et al., 102 
2017). Investigators have used autophagy and apoptosis cross regulation to develop new 103 
therapeutic approaches for cancer. For example, different autophagy inducers and inhibitors have 104 
been used with chemotherapy agents, and radiotherapy to increase the efficiency of cancer 105 
therapy in some patients (Hombach-Klonisch et al., 2018; Mokarram et al., 2017).  106 
We have previously studied cell death mechanisms of statins in airway smooth muscle and 107 
recently established a research program in developing new therapeutic approaches for 108 
Rhabdomyosarcoma (RMS). Previous investigations have used C2C12 mouse myoblasts 109 
(Jaskiewicz et al., 2019; Schirris et al., 2015a) as a model for investigation of statins myopathy. 110 
In the current study, we aim to understand the myotoxic effects of statins, using the 111 
rhabdomyosarcoma cell line (RH30) (Moghadam et al., 2018) as well as C2C12 cell lines to 112 








MATERIALS and METHODS 121 
Chemicals and Antibodies 122 
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M2128), 123 
simvastatin (S6196), FPP (F6892), GGPP (G6025), cholesterol (47129), mevalonate (68519), 124 
LC3β antibody (L7543), and beta actin antibody (A2228) were purchased from Sigma/Aldrich 125 
(Canada, Ontario) Dimethyl sulfoxide (DMSO) (4948-02) were purchased from VWR (Canada, 126 
Ontario). SQSTM1/p62 antibody (5114) were purchased from cell singling (Canada Ontario). 127 
Cleaved PARP (Asp214) (D64E10) XP® Rabbit mAb, LC3B (D11) XP® Rabbit mAb, and 128 
SQSTM1/p62 (D5L7G) Mouse mAb were purchased from Cell Signaling Technology. Alexa 129 
Fluor® 488 AffiniPure Donkey Anti-Rabbit IgG, and Alexa Fluor® 647 AffiniPure Donkey 130 
Anti-Mouse IgG secondary antibodies and IgG-free bovine serum albumin (BSA) were 131 
purchased from Jackson ImmunoResearch Inc. DAPI (4',6-Diamidino-2-Phenylindole, 132 
Dihydrochloride) was purchased from Thermo Fisher Scientific. Bovine type 1 collagen (10 133 
mg/mL) was purchased from Advanced BioMatrix Inc. Live/dead viability staining kit was 134 
purchased from Millipore Sigma. 135 
 136 
Cell Lines and Cell Culture 137 
 The human rhabdomyosarcoma cell line (RH30) [RC13, RMS 13, SJRH30] (ATCC® 138 
CRL¬ 2061™) (Human muscle cancer cells) and mouse muscle cell line (C2C12) (ATCC® 139 
CRL¬1772™) were used in this project. Cells were cultured in Roswell Park Memorial Institute 140 
(RPMI- 1640) with L-glutamine and 25mM HEPES (BioWhittaker; Cat #: 12-115Q) and 141 
Dulbecco’s Modified Eagle’s Medium (DMEM) (CORNING; Cat #: 50-003-PB) with 10% fetal 142 
bovine serum (FBS) (Gibco™; Cat #: 16000044). RH30 cell lines were cultured in RPMI-1640 143 
with L-glutamine and 25 mM HEPES media, and C2C12 cells were cultured in DMEM with 144 
high glucose media. Both media were supplemented with FBS (10%), penicillin (1%), and 145 
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streptomycin (1%). Cells were grown to 35–40% confluency on a 100 mm cell culture plate, 6-146 
well plates, and 96-well plates. Cells were maintained in a humidified incubator with 95% air 147 
and 5% CO2 at 37 °C and were passed once every 2–3 days. Cell culture plastic ware, penicillin, 148 
and streptomycin were purchased from VWR (Toronto, ON, Canada).  149 
 150 
MTT Assay 151 
The MTT assay was performed based on a protocol established in our group (Alizadeh et 152 
al., 2017; Ghavami et al., 2004; Ghavami et al., 2010b; Ghavami et al., 2012a; Ghavami et al., 153 
2011; Ghavami et al., 2014). Briefly C2C12 (20,000 cells/mL) and RH30 (30,000 cells/mL) were 154 
seeded in 96-well plates and treated with varying concentrations of simvastatin (Simva, 0-20 155 
M). At each time-point (24, 48, 72, and 96 hrs), 20 L of (MTT, 5 mg/ml) was added to each 156 
well. The cells were incubated at 37C for 4 hours, after which the media was gently aspirated. 157 
Then, 200 L of DMSO was added to each well and mixed with the cells by pipetting to dissolve 158 
the MTT formazan crystals. Lastly, the plates were incubated for 20 min at room temperature. 159 
Absorbance was measured at 570 nm using a Synergy H1 Microplate Reader. 160 
 161 
Mevalonate Cascade Rescue Assay  162 
Rescue experiments were done according to previously reported protocols (Alizadeh et 163 
al., 2017; Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014).  Briefly, cells 164 
were seeded and grown in 96-well plates at a density of 2,000 cells per well, up to 50% 165 
confluence. Cells were pre-treated with 5 mM mevalonate (MeV), 30 μM FPP, 30 μM GGPP, 166 
and 50 μM cholesterol, and were incubated at 37°C for 4 hrs. These cells were then co-treated 167 
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with 10 μM Simvastatin and incubated at 37°C for 96 hrs. Cell viability was then measured using 168 
the MTT assay after 96 hrs, as described in the previous section. 169 
 170 
Immunoblotting 171 
Western blotting analysis of C2C12 and RH30 cell lysates was used to assess markers of 172 
autophagy (LC3 (1:2500), p62 (1:1000)) as has been described in our previous studies (Ghavami 173 
et al., 2010b; Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014). Cells were 174 
grown to 40-50% confluency in 100 mm dishes and either treated with 10 M Simva or with a 175 
drug vehicle control (DMSO). At the appropriate time point, cells were collected, and protein 176 
extracts were made using NP-40 Lysis Buffer (0.5% (v/v) Nonidet P-40, 20 mM Tris-HCl (pH 177 
7.5), 0.5% (v/v) PMSF, 100 M -glycerol 3-phosphate and 1.5% (v/v) protease inhibitor 178 
cocktail). Once the protein concentration was known, samples were prepared for western blotting 179 
with a total protein concentration of 1 g/L (15 L of each sample was used). After 180 
electrophoresis, the membranes were developed for LC3β and p62 proteins. 181 
  182 
Measurement of Apoptosis with Flow Cytometry  183 
 We measured apoptosis using the Nicoletti method. C2C12 and RH30 cells were cultured 184 
in 6-well plates and treated with either Simva (5 or 10 M) or with a drug vehicle control 185 
(DMSO) for 48 hrs. After drug treatment, cells were detached using EDTA buffer and 186 
centrifuged at 1,500 g for 5 min at 4C. Cells were washed with cold PBS before they were 187 
permeabilized and stained with a hypotonic Propidium Iodide (PI) buffer (0.1% Triton X-100, 188 
1% sodium citrate, 0.5 mg/ml RNase A, 40 μg/ml propidium iodide). Samples were then 189 
incubated for 1 hour in the dark at 4C to prevent photo-bleaching. Flow cytometry was carried 190 
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out at 460 nm for 10,000 cells. Residual debris were gated out accurately to obtain accurate data. 191 
The resulting histogram was analyzed to determine the percentage of normal and apoptotic 192 
nuclei; the nuclei of apoptotic cells were located on the left side of the G1 peak as they have less 193 
DNA compared to the nuclei of healthy G0/G1 cells. For each sample, the sub-G1 peak was 194 
measured and statistically compared with other samples to determine significance (Hashemi et 195 
al., 2007; Moghadam et al., 2018). 196 
 197 
Live Cell Imaging  198 
 LC3 is a specific marker for autophagosomes, which are key structures in the process of 199 
autophagy. LC3-GFP is a fusion of green fluorescent protein (GFP) and LC3, and it can behave 200 
in the same manner as endogenous LC3. LC3-GFP is localized on the autophagosome membrane 201 
and emits green light when excited. In a normal cell, LC3 is dispersed evenly through the 202 
cytosol. However, when autophagic flux is initiated, LC3 is recruited to autophagosome 203 
membranes, resulting in sharp green puncta and LC3-GFP-containing cells. To confirm 204 
autophagy findings seen in western blots, C2C12 or RH30 cells were grown in 6-well plates and 205 
transfected with a plasmid containing LC3-GFP (Addgene #24920) using Qiagen’s Effectene 206 
reagent, as per manufacturer’s instructions. After transfecting cells for 18 hrs, the cells were 207 
treated with either Simva (10 M), Bafilomycin-A1 (Baf-A1, 100 nM), Simva + Baf-A1, or a 208 
vehicle control (DMSO). After 24 hrs, the cells were incubated with LysoTracker red dye 209 
(Molecular Probes; LysoTracker Red DND-99; L7528) at a concentration of 50 nM to detect 210 
lysosomal activity and counterstained with Hoechst. Cells were stained for 30 min in a 37C 211 
incubator. After the 30 min period, the cells were washed with PBS and fresh media was added. 212 
The cells were imaged on an epifluorescence microscope. Images were analyzed to determine the 213 
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percentage of cells with distinct LC3-GFP puncta and to see if green and red puncta co-214 
localization had occurred, which was assumed to signify the fusion of autophagosomes with 215 
lysosomes (Field et al., 2018; Moghadam et al., 2018). 216 
 217 
Transmission Electron Microscopy (TEM) 218 
 TEM was used to evaluate autophagy in both C2C12 and RH30 cell lines. The TEM 219 
protocol is the same as previously described1. Briefly, cells were grown in 10 mm dishes 220 
(300,000 cells/dish) and treated with either DMSO (drug vehicle control) or 10 M Simva for 48 221 
hrs. At the time point, cells were detached with EDTA and centrifuged at 1,500 g. The samples 222 
were then fixed with 3% glutaraldehyde in PBS (pH 7.4) for 3 hrs at room temperature. The 223 
samples were later treated post-fixation with 1% osmium tetroxide in PBS for 2 hrs, followed by 224 
an alcohol dehydration series, and then embedded in Epon and stained with uranyl acetate. They 225 
were counterstained with lead citrate for 3 min sequentially and finally washed with water for 1 226 
min and dried. The samples were imaged on a Philips CM10 at 80kV on ultra thin sections 227 
(100nm on 200 mesh grids) (Alizadeh et al., 2018a; Moghadam et al., 2018).  228 
 229 
Culturing C2C12 and RH30 cells in 3D cultures 230 
 C2C12 and RH30 cells were grown in 3D culture according to the same protocol 231 
explained in previous publications (Moghadam et al., 2018). Briefly, cells were grown in culture 232 
medium (DMEM or RPMI with 10% FBS and 0.5% Pen-Strep) until they reached 80% 233 
confluency. Cells were detached with Trypsin-EDTA, spun down, and re-suspended in fresh 234 
media. Collagen and media were gently added to the cell suspension at 4C to reach a final 235 
collagen concentration of 3 mg/mL and a cell density of 2 million cells/mL. Then, 20 L of this 236 
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solution was added to cylindrical wells with 5 mm diameter and 1 mm depth in PDMS holders 237 
which were placed in 12 well-plates and put in a 37C incubator for 45 min to cure the collagen. 238 
Afterwards, 2 mL of media was added to each well and they were incubated overnight. The next 239 
day, cells were treated with either DMSO or Simva (Moghadam et al., 2018).  240 
 241 
Live-Dead Assay in 3D Culture 242 
 Cells were grown and treated as explained above. Live-dead assay solution was prepared 243 
as per the supplier’s instructions, where 5 L of calcein and 20 L of ethidium homodimer-1 244 
were added to 10 mL of DPBS. After treatment, media was removed, and the live-dead solution 245 
was added to the wells. After incubating for 2 hrs at room temperature in the dark, the solution 246 
was removed and the cells were gently rinsed with DPBS three times, each time with 5 min 247 
incubation. Stained cells were then imaged on a confocal microscope and quantified (Moghadam 248 
et al., 2018).  249 
 250 
Immunofluorescence (IF) in 3D Culture 251 
 IF was used to confirm apoptosis and autophagy findings by evaluating cleaved-PARP, 252 
LC3, and p62 levels. C2C12 and RH30 cells were treated with DMSO or 10 M Simva for 96 or 253 
48 hrs, respectively. At the appropriate time point, media was removed, and cells were fixed by 254 
incubating them with 4% paraformaldehyde in PBS for 15 min at room temperature. 255 
Paraformaldehyde was then removed, and cells were washed 3 times with PBS. Cells were 256 
blocked with blocking buffer (5% goat serum, 0.3% Triton-X in RBS) at room temperature. 257 
After 60 to 120 min, blocking buffer was removed and the appropriate primary antibody—p62, 258 
LC3, or c-PARP –was diluted 1:300 in Antibody Buffer (1% BSA, 0.3% Triton-X in PBS) and 259 
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incubated with the samples overnight at 4C. The next day, the antibody solution was removed, 260 
and cells were washed three times with PBS. Cells were then incubated with the appropriate 261 
fluoro-conjugated secondary antibody which was diluted 1:400 in Antibody Buffer. Samples 262 
were incubated in the dark for 2 hrs at room temperature, and then washed with PBS. Finally, the 263 
cells were incubated with DAPI solution for 1 hr in the dark. After washing three times with 264 
PBS, cells were immediately taken for imaging (Moghadam et al., 2018).  265 
 266 
Statistical Analysis 267 
All results were presented as mean ± SD, and the differences between the groups were 268 
tested by one-way ANOVA or two-way ANOVA analysis (non-parametric, Brown–Forsythe 269 
test), using GraphPad Prism 7.0. The confidence interval in each analysis was 95%, and p < 0.05 270 








Mevalonate Cascade Inhibition Induces Cell Death in Both RH30 and C2C12 Cells 279 
We previously showed that the MA cascade inhibitor simvastatin induces cell death in a 280 
broad range of primary cells (primary airway mesenchymal cells, and primary atrial fibroblasts) 281 
(Ghavami et al., 2010b; Ghavami et al., 2011; Ghavami et al., 2014) and tumor cell lines 282 
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(Alizadeh et al., 2018b; Alizadeh et al., 2017; Sheikholeslami et al., 2019) including breast 283 
(MCF-7, MDA-MB231), brain (U87, U251), and lung (A549, H1965), as well as 284 
medulloblastoma brain tumor cell lines (Daoy, D283, and D341 cells). Lovastatin and 285 
mevalonate cascade inhibitors (GGTi-298, 6-Fluoromevalonate) also inhibit ovarian cancer 286 
tumor growth (Kobayashi et al., 2017; Kobayashi et al., 2015).  287 
We now demonstrate that simvastatin induces dose- (0-20 µM) and time- (0-96 hr) 288 
dependent cell death in both RH30 (Fig. 1 A-D) and C2C12 cells (Fig. 1 E-H). In RH30 cells, 289 
simvastatin (20 µM) significantly induced cell death (p < 0.05) in 24 hrs (Fig. 1 A), simvastatin 290 
(10, 20 µM) significantly induced cell death (p < 0.0001) in 48 hrs (Fig. 1 B), simvastatin (5,10, 291 
20 µM) significantly induced cell death (p <0.05, p < 0.0001) in 72 and 96 hrs (Fig. 1 C&D). 292 
Interestingly, simvastatin (0.5-20 µM) induced significant cell death (p < 0.001, p <0.0001) in all 293 
time points (24-96 hr) in C2C12 cells (Fig.1 E-H). The morphology of RH30 cells treated with 294 
simvastatin (10 µM) is shown in Fig. 1J and compared with RH30 time-matched control. 295 
Simvastatin at concentrations of ≥2.5 µM induced significant cell death in C2C12 cells as 296 
compared to RH30 cells (p < 0.01).  297 
 298 
Prenylation Precursors Differentially Control Simvastatin-Induced Cell Death in C2C12 and 299 
RH30 Cells.  300 
We know that mevaloante (MEV) can reverse statin-induced cell death in many cell 301 
models, and GGPP is the major regulator of prenylation events among the isoprenoid 302 
intermediates. We now show that MA (5 mM) significantly (p < 0.0001) inhibits simvastatin- 303 
(10 µM) induced cell death in both C2C12 (Fig. 2 A) and RH30 (Fig. 2E) cells. While GGPP (30 304 
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µM) significantly (p < 0.0001) inhibited simvastatin-induced cell death in both C2C12 (Fig. 2B) 305 
and RH30 (Fig 2F) cells, it was more effective in rescuing RH30 cells than C2C12 cells (Fig. 306 
2J). We found that FPP (30 µM) did not significantly inhibit simvastatin-induced cell death in 307 
C2C12 cells (Fig. 2C), but it did significantly (p < 0.01) inhibit simvastatin-induced cell death in 308 
RH30 cells (Fig. 2G). FPP was also more effective in rescuing RH30 cells against simvastatin-309 
induced cell death (Fig. 2K). Furthermore, cholesterol (50 µM) did not significantly inhibit 310 
simvastatin-induced cell death in either C2C12 (Fig. 2D) or RH30 (Fig. 2I). 311 
 312 
Mevalonate Cascade Inhibition Induces Apoptosis in Both C2C12 and RH30 Cells 313 
Mevalonate cascade inhibition can induce apoptosis in many cell models (Alizadeh et al., 314 
2018b; Alizadeh et al., 2017; Ghavami et al., 2010b; Ghavami et al., 2012b). In this study, we 315 
show that simvastatin induces dose- (5, 10 µM) and time-depended (48, 72 hr) apoptosis in both 316 
C2C12 (Fig. 3A-C) and RH30 (Fig. 3D-F) cells (p < 0.01, p < 0.0001). We also show that 317 
simvastatin significantly induces greater apoptosis in RH30 cells as compared to C2C12 cells 318 
(Fig. 3G) (p < 0.01). 319 
Mevalonate Cascade Inhibition Induces Blockage of Autophagy Flux in Both C2C12 and RH30 320 
Cells While Inhibiting the Acidification of Lysosomes in C2C12 Cells 321 
Statins can induce autophagy in different types of cells (Ghavami et al., 2011; Ghavami 322 
et al., 2014; Ghavami et al., 2012b). Our current study shows that statins inhibit autophagy flux 323 
in both RH30 and C2C12 cells. We show that simvastatin (10 µM) increases LC3 lipidation and 324 
induced p62 accumulation in both RH30 and C2C12 cells (Fig. 4A). To further confirm our 325 
results, using GFP-LC3 and lysotracker immunostaining, we show that simvastatin induced 326 
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significant increase of LC3 puncta in both C2C12 and RH30 (Fig. 4B-D) while in C2C12 cells 327 
prevented acidification of lysosomes (Fig. 4B) (lack of lysotracker red activity in simvastatin-328 
treated cells). We further confirmed our results using the autophagy inhibitor Bafilomycin A1 329 
(Baf-A1, 100 nM for 1 hr) and show that adding Baf-A1 does not significantly increase the 330 
number of LC3 puncta in both C2C12 (Fig. 4 E&G) and RH30 cells (Fig 4 F&H). We also 331 
confirmed increased numbers of autophagosomes in both C2C12 (Fig. 4I) and RH30 cells (Fig 332 
4J). We then used Baf-A1 (4 nM) in presence and absence of simvastatin (10 µM, 24 hrs) in 333 
C2C12 and RH30 cells (Fig 4K). Immunoblotting results confirmed further inhibition of 334 
autophagy flux in both C2C12 and RH30 cells (increase of LC3β lipidation and decrease of p62 335 
degradation) (Fig 4K). Further, inhibition of autophagy significantly increased simvastatin-336 
induced myotoxicity in both C2C12 and RH30 cells (Fig 4L&M).  337 
 338 
Simvastatin Induces Apoptotic Cell Death and Inhibits Autophagy in Both C2C12 and RH30 339 
Cells in 3D Culture 340 
Cells cultured in 3D configurations using hydrogel biomaterials display a more 341 
physiologically-relevant phenotype (Seyfoori et al., 2018). We recently showed that 3D-cultured 342 
C2C12 and RH30 cells can be used to screen drugs (Moghadam et al., 2018). In this study, we 343 
used this same 3D technique to evaluate the effect of simvastatin on C2C12 and RH30 cells. We 344 
performed live/dead assays in 3D culture of C2C12 and RH30 cells and show that simvastatin (5, 345 
10 µM) induces both dose- and time- (48, 96 hrs) dependent cell death (Fig. 5 A-H). Also, 346 
simvastatin induced significant (p < 0.0001) cell death in both C2C12 (Fig. 5 A, C, E&F) and 347 
RH30 (Fig. 5 B, D, G, H) cells in the 3D model. However, when cultured in the 3D hydrogel, 348 
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simvastatin induced more cell death in RH30 cells as compared to C2C12 cells. This was 349 
opposite to the effect we observed when such cells were culture in standard 2D conditions. In 350 
addition, simvastatin (10 µM) induces apoptotic cell death in both C2C12 and RH30 cells 351 
(cleavage of PARP) in the 3D culture model (Fig. 5 I, J). We further investigated the effects of 352 
simvastatin on autophagy in both C2C12 and RH30 3D culture cells. We showed that 353 
simvastatin inhibits autophagy flux in 3D culture model (increase of LC3 puncta and lack of 354 








Our previous studies have demonstrated that the HMG-CoA reductase inhibitor simvastatin 363 
induces endoplasmic reticulum stress/unfolded protein response, autophagy, and apoptosis in 364 
human airway smooth muscle (HASM) cells, human airway fibroblasts (HAF), and human atrial 365 
fibroblasts through inhibition of GGPP biosynthesis (Ghavami et al., 2012a; Ghavami et al., 366 
2011; Ghavami et al., 2014). Previously, we also showed that simvastatin induces apoptotic cell 367 
death in a wide variety of tumor cells (lung, brain, and breast) via inhibition of 368 
geranylgeranylation of small Rho GTPases (Alizadeh et al., 2017) .  369 
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Statin-induced myotoxicity is a major concern for clinicians and basic scientists alike, and 370 
several recent investigations have focused on the possible underlying mechanisms involved in 371 
statin myotoxicity. In the current investigation, we used C2C12 as our non-cancerous cell line 372 
and RH30 as a cancer skeletal muscle cell line to elucidate the mechanisms underlying 373 
simvastatin-induced myotoxicity. Our experiments utilized both monolayer 2D and 3D cell 374 
culture models, which are more physiologically relevant accounting in part for the cellular 375 
microenvironment.  376 
Previous investigations have demonstrated that statin-induced myotoxicity occurs via 377 
vacuolation of skeletal muscle fibers, blebbing of sarcolemma, and cell necrosis (Sakamoto et 378 
al., 2007). Inhibition of the mitochondrial complex III is involved in statin-induced myotoxicity 379 
in C2C12 cells (Schirris et al., 2015b). Other reports indicated that mitochondria (Bouitbir et al., 380 
2012; Kwak et al., 2012; Schirris et al., 2015b), Ca2+ homeostasis (Sirvent et al., 2012), plasma 381 
membrane mono-carboxylate transporter (Kobayashi et al., 2006), plasma membrane receptors 382 
(Dricu et al., 1997; Siddals et al., 2004), and ubiquitin ligases (Cao et al., 2009) are statins’ 383 
primary targets for myotoxicity. Here we show that simvastatin induced cell death in both 384 
C2C12 and RH30 cells. However, there were significant differences between C2C12 and RH30 385 
in cell viability (MTT assay) after treatment with simvastatin in 2D monolayer cell culture 386 
(simvastatin caused significantly greater reduction in C2C12 cell viability as compared to 387 
RH30). Since the MTT assay is based on the measurement of mitochondrial reductase activity to 388 
produce formazon, our results suggest that simvastatin-induced cell death may be dependent on 389 
the decrease of reductase activity in C2C12 cell lines. Of note, statin-induced myotoxicity 390 
(Graham et al., 2004) is augmented with the combination of drugs that block metabolic pathways 391 
and decrease mitochondrial reductase activity in cells, such as cytochrome P450 and UDP-392 
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glucuronyltransferase 1A1 and 1A3 systems (Prueksaritanont et al., 2002). Consistent with 393 
previous studies, our results demonstrate that simvastatin has greater myotoxicity in C2C12 394 
(non-cancerous muscle) cells than RH30 (skeletal muscle cancer) cells.  395 
We also show that simvastatin induced apoptosis in a time- and dose-dependent manner in 396 
both C2C12 and RH30 cells. Interestingly, RH30 was more susceptible to apoptosis than C2C12 397 
in 2D monolayer culture model (Figure 3). The rate of simvastatin-induced apoptosis in RH30 398 
cells was ~2-fold greater than the C2C12 cell line. Therefore, while simvastatin caused a 399 
reduction in cell viability in C2C12 cells, these cells were also less susceptible to apoptosis than 400 
RH30 cells. This is not unexpected given that in the broader statin-cancer literature, cancer cells 401 
are predominantly more sensitive to statin-induced cell death than their normal or non-cancerous 402 
controls. These results intriguingly show that simvastatin-induced apoptosis in skeletal muscle 403 
cells does not correlate with loss of cell viability as measured by the MTT assay; this suggests an 404 
effect mediated via other mitochondrial factors. For example, in our previous investigations we 405 
showed that simvastatin-induced apoptosis is dependent on the release of Smac/Diablo and 406 
Omi/Htr2 from mitochondria in HASM cells and HAF (Ghavami et al., 2010b) and is 407 
independent of the release of cytochrome c from mitochondria.  408 
The role of cholesterol biosynthesis in statin-induced cell death has been widely 409 
investigated and those results are consistent with ours (Graham et al., 2004; Sakamoto et al., 410 
2007; Schirris et al., 2015b). Previous studies showed that statins reduce GGPP levels and 411 
production of ubiquinones which are used as electron carriers in the electron transport chain 412 
(Harper and Jacobson, 2007; Thompson et al., 2003). Consequently, the decrease of ubiquinone 413 
production in cells leads to dysfunction of the electron transport chain, which reduces muscle 414 
cell ATP levels, elevates free radical production, and induces apoptosis (Harper and Jacobson, 415 
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2007; Thompson et al., 2003). Further, the impaired geranylgeranylation of proteins may be a 416 
root cause in statin-associated myopathy (Cao et al., 2009; Johnson et al., 2004; Mullen et al., 417 
2010), a concept contested by work carried out in rhabdomyosarcoma rather than normal skeletal 418 
muscle cells (Gee et al., 2015). Therefore, we decided to investigate the MA pathway in both 419 
C2C12 and RMS cells. In our study, co-treatment with MA or GGPP inhibited simvastatin-420 
induced cell death in the C2C12 cell line while co-treatment with cholesterol and FPP did not. 421 
Takeda et al. demonstrated that the reduction of smooth muscle cell proliferation by simvastatin 422 
was inhibited by GGPP, but not by FPP (Takeda et al., 2006). Their findings are compatible with 423 
our results which show simvastatin signaling is dependent on GGPP in C2C12 cells. Our present 424 
study also shows that in RH30 cells simvastatin-induced cell death is inhibited by MA and 425 
GGPP, but not cholesterol (Fig 2). Unlike in C2C12 cells, we show that in RH30 cells 426 
simvastatin-induced cell death was inhibited by FFP (Fig 2). These findings confirm that the 427 
effect of simvastatin on cell death in both cells was mediated via inhibition of the MA pathway, 428 
in particular, GGPP. In addition, we discovered that FPP may play an important role in 429 
simvastatin-induced death mechanisms in RH30 cells.  430 
GGPP and FPP are necessary for the prenylation of small Rho GTPase proteins including 431 
Rho, Rac, Cdc42, Rab and Rac (Alizadeh et al., 2018b; Alizadeh et al., 2017; Ghavami et al., 432 
2010b; Ghavami et al., 2012a; Yeganeh et al., 2014). We show that simvastatin-induced cell 433 
death is dependent on GGPP in C2C12 cells. This indicates that Rho, Cdc42, and Rac GTPases 434 
may be involved in cell death induction mechanisms in C2C12 cells. Conversely, in RH30 cells 435 
both FPP and GGPP mediate simvastatin-induced cell death, suggesting that Ras GTPases may 436 
also be involved via farnesylation pathways.  437 
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Several recent investigations have shown that HMG-CoA reductase inhibitors such as 438 
simvastatin either induce or inhibit autophagy in different cell models (Ghavami et al., 2014; 439 
Hwang et al., 2015; Vilimanovich et al., 2015; Whitehead, 2016).  There are two recent articles 440 
that showed hydrophobic statins induced autophagy in A204 RMS cells (Araki and Motojima, 441 
2008; Gee et al., 2015). But, the exact molecular mechanisms of the autophagy flux, 442 
autophagosome fusion and degradation steps of autophagy have not been investigated in RMS 443 
cells.  Many studies demonstrated that the LC3-II/LC3-I ratio is often used to determine the 444 
activation of autophagy (Mizushima et al., 2010). The present results show that simvastatin 445 
increased the conversion of light chain 3 (LC3)-I to LC3-phosphatidylethanolamine conjugate 446 
(LC3-II) in both C2C12 and RH30 cells by increasing the number of LC3 puncta 447 
(immunofluorescence) and autophagosome formation (Figure 4). The protein p62 facilitates the 448 
degradation of ubiquitinated protein aggregates by autophagy (Guo et al., 2013) and is a selective 449 
substrate for autophagy and directly interacts with LC3 to mediate the degradation of 450 
ubiquitinated protein aggregates by autophagy (Pankiv et al., 2007). Our results show that 451 
simvastatin increases p62 accumulation in both RH30 and C2C12 cell lines, therefore, 452 
simvastatin inhibits autophagy flux in both cells lines. Moreover, our results showed that 453 
simvastatin induced acidification of lysosomes in RH30 cells, but in C2C12 cells simvastatin 454 
inhibited acidification of lysosomes (Fig. 4B). Taken together, our data demonstrates that 455 
simvastatin inhibits autophagy flux in a time-dependent manner in both non-cancer C2C12 and 456 
RMS RH30 cells. Therefore, we conclude that simvastatin inhibits autophagy flux in both 457 
C2C12 and RH30. In RH30 cells, autophagy inhibitory activity occurs via inhibition of 458 
lysosomal acidification, however, further investigation is required to prove this hypothesis. 459 
Further blockage of autophagy flux increases the myotoxicity of simvastatin in both C2C12 and 460 
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RH30 cells. These findings confirm the importance of autophagy flux inhibition in the 461 
myotoxicity of statins. These results are inconsistent with our findings in HAF and HASM 462 
(Ghavami et al., 2011; Ghavami et al., 2014). Also, Gu et al showed that simvastatin induces 463 
autophagy in bronchial smooth muscle cells (BSMCs) and increases autophagy-related protein 464 
Atg5, LC3B, and Beclin1 expression and autophagosome formation in lung tissue (Gu et al., 465 
2017). 466 
The effect of chemical compounds on cells have mostly been performed using 2D cell 467 
culture models, where cell-cell interaction, extracellular matrix, and cellular morphology 468 
significantly differ from their natural structure in tissues (Levinger et al., 2014). These 469 
differences highly influence cellular growth and their response to different chemical compounds 470 
(Levinger et al., 2014). Three-dimensional (3D) culture models have been introduced for drug 471 
assessment to improve the relation between cell cultures and cellular microenvironment 472 
(Friedrich et al., 2009). Recently, 3D culture models have been used as clinically relevant models 473 
for the study of cell death and autophagy (Gomes et al., 2015; Ma et al., 2011). We examined the 474 
effects of simvastatin in RH30 and C2C12 3D culture models (Fig. 5), which showed that 475 
simvastatin induces significantly greater cell death in RH30 cells as compared to C2C12 cells. 476 
Whereas, the cell death effects of simvastatin were greater in C2C12 cells as compared to RH30 477 
cells in the 2D cell culture model. This shows how the cell microenvironment and 3D structure 478 
can affect fundamental cellular response(s) including to chemical compounds or drugs. We also 479 
observed that simvastatin inhibits autophagy flux in 3D culture of RH30 and C2C12 cells 480 
(absence of localization of p62 and LC3 puncta) which correlates with our 2D observations. 481 
Overall, our results indicate that 3D culture models are important tools for screening cytotoxic 482 
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effects of chemical compounds as they can account for some of the effects of cellular matrix in 483 
response to extracellular stress. 484 
 There are several limitations to this study that are important to mention. The dose of 485 
simvastatin used in our experiments (10 M) is significantly higher than pharmacologic 486 
concentrations found in human blood which is in the low nanogram/mL (nM) range (Ucar et al., 487 
2000). However, we don’t know if statins accumulate in human skeletal muscle, and whether 488 
they reach micromolar concentrations. Furthermore, simvastatin’s half-life is approximately 2 489 
hours in plasma, and results can vary according to which statin is selected. In addition, normal 490 
human skeletal muscle behaves differently than rhabdomyosarcoma cell line, so the effects 491 
observed could manifest differently in human normal skeletal muscle.  492 
In conclusion, we found that simvastatin induces cell death in both RH30 and C2C12 cells 493 
in both 2D and 3D culture. Our results showed that simvastatin significantly decreases cellular 494 
viability in C2C12 cells compared to RH30 cells while it also significantly induces greater 495 
apoptosis in RH30 cells compared to C2C12 cells. In addition, simvastatin inhibits autophagy 496 
flux in both RH30 and C2C12 cells with differential effects on lysosomal acidification. We also 497 
showed that simvastatin-induced cell death is dependent on both FPP and GGPP in RH30 cells 498 
while it is only dependent on GGPP in C2C12 cells. Our current investigation provides solid 499 
evidence that both autophagy and apoptosis are involved in statin-induced myotoxicity, and 500 
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FIGURE LEGENDS:  512 
Figure 1: Simvastatin induces cell death in RH30 and C2C12 cells. (A-D). RH30 cells were 513 
treated with simvastatin (0.5, 1, 2.5, 5, 10, 20 μM) and cell viability was assessed 24, 48, 72 and 514 
96 hrs after that by MTT assay. Control cells for each time point were treated with the solvent 515 
control (DMSO). Results are expressed as a percentage of corresponding time point control and 516 
represent the means  SD of 15 replicates in three independent experiments (*, p<0.05; ****, 517 
p<0.0001). (E-H). C2C12 cells were treated with simvastatin (0.5, 1, 2.5, 5, 10, 20 μM) and cell 518 
viability was assessed 24, 48, 72 and 96 hrs after that by MTT assay. Control cells for each time 519 
point were treated with the solvent control (DMSO). Results are expressed as a percentage of 520 
corresponding time point control and represent the means  SD of 15 replicates in three 521 
independent experiments (****, p<0.0001). (I&J). Simvastatin significantly decreased cell 522 
viability in C2C12 compared to RH30 cells. RH30 and C2C12 cells were treated with 523 
simvastatin (0.5, 1, 2.5, 5, 10, 20 μM) and cell viability was assessed 24, 48, 72 and 96 hrs after 524 
that by MTT assay. Control cells for each time point were treated with the solvent control 525 
(DMSO). Results are expressed as a percentage of corresponding time point control and 526 
represent the means  SD of 15 replicates in three independent experiments (****, p<0.0001). 527 
(K&L). Phase contrast microscopy showed that simvastatin (10 µM, 48 hrs) induces 528 
morphological changes (cellular shrinkage) and decrease in the number of cells in RH30 cells.  529 
 530 
Figure 2: Simvastatin induces cell death in RH30 and C2C12 cells is dependent on 531 
mevalonate cascade isoprenoid mediators. (A-H) 5 mM MA, 30 µM GGPP, 30 µM FPP, or  532 
50 M cholesterol, were added to the cells 4 hrs prior to treatment with simvastatin (10 M, 96 533 
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hrs). Cell death was measured by MTT assay in C2C12 (A-D), and RH30 cells. For each 534 
experiment control cells were treated with simvastatin solvent (DMSO) alone (control) or with 535 
both DMSO and the appropriate solvent (i.e. ethanol for “mevalonate control). Mevalonate (A, 536 
E) and GGPP (B, F) significantly inhibited simvastatin induced cell death in both C2C12 and 537 
RH30 cells while FPP (C, G) only inhibited simvastatin-induced cell death in RH30 cells. Our 538 
results also showed that cholesterol (D, H) is not involved in simvastatin induced cell death in 539 
C2C12 and RH30 cells. Results are expressed as mean ± SD of 15 replicate in 3 independent 540 
experiments (* p< 0.05, *** p< 0.001, and ****p < 0.0001). (I&J) Our results also showed that 541 
FPP (I) and GGPP (J) significantly rescues simvastatin induced cell death in RH30 cells 542 
compared to C2C12 cells.  543 
 544 
Figure 3: Simvastatin induces dose and time depended apoptosis cell death in C2C12 and 545 
RH30 cells. Percent sub-G1 (A-C) C2C12, (D-F) RH30, abundance induced by simvastatin (5, 546 
and 10 μM) or DMSO solvent control after 48 and 72 hrs. Results represent the means ± SD of 9 547 
replicates in three independent experiments. ****p< 0.0001; and ***p< 0.001 compared to time-548 
matched control. Representative figures of the flow cytometry histogram for C2C12 and RH30 549 
are shown (A and D). Our results showed that simvastatin (10 µM) induced significant more 550 
apoptosis in RH30 compared to C2C12 cells in 48 (G) and 72 (H) hours (** p< 0.01, and **** p 551 
< 0.0001).  552 
 553 
Figure 4: Simvastatin inhibits autophagy flux inhibition in C2C12 and RH30 cells. (A) 554 
C2C12 and RH30 cells were treated with simvastatin (10 µM, 0-72 hours) and cell lysates were 555 
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collected. Immunoblotting for LC3β and p62 were performed. The results showed that 556 
simvastatin induced accumulation of LC3β II and inhibits p62 degradation in both C2C12 and 557 
RH30 cells. C2C12 and C2C12 cells were treated with simvastatin (10 μM, 24 h). (B-D) using 558 
immunocytochemistry LC3 puncta and changes in lysosomal activity (LysoTracker red staining) 559 
has been investigated. The results showed that simvastatin increased LC3 puncta in both cell 560 
lines. Our results also showed that simvastatin (10 µM, 24 hours) increase lysosomal acidity in 561 
RH30 while inhibits lysosomal acidification in C2C12 cells (B).  C2C12 (E) and RH30 (F) cells 562 
were treated with simvastatin (10 μM, 24h) and Baf-A1 (100 nM, +3 hours) followed by 563 
immunocytochemistry to evaluate LC3 puncta and changes in lysosomal activity (LysoTracker 564 
red staining). The results showed that simvastatin increased LC3 puncta and decreased 565 
LysoTracker red fluorescence intensity in C2C12 cells while increased LC3 puncta and increased 566 
LysoTracker red fluorescence intensity in RH30 cells. On the other hand, Baf-A1 and 567 
simvastatin + Baf-A1 did not significantly change LC3 puncta in both C2C12 and RH30 cells (G, 568 
H) showing that simvastatin inhibited autophagy flux like Baf-A1. Transmission electron 569 
microscopy showed that in treated C2C12 (I) and RH30 (J) cells there are accumulated 570 
autophagosome-like structures compared to control and normal cells after 72 hours treatment. 571 
Arrows show the autophagolysosomes containing the cargo (magnification ×11,600). Autophagy 572 
inhibition (Baf-A1, 4 nM, 24 hours) significantly increased simvastatin-induced cell death (10 573 
µM, 24 hours) in RH30 (L) and C2C12 (M) cell lines (** p < 0.01, Results represent the 574 
means ± SD of 15 replicates in three independent experiments). Baf-A1 (4 nM) and simvastatin 575 
(10 µM) combination did not increase accumulation of LC3β-II and p62 in both RH30 and 576 




Figure 5: Simvastatin induces apoptosis and autophagy in C2C12 and RH30 3D culture. 579 
(A&B). Bright field image of C2C12 (A) and RH30 (B) 3D culture which shows the morphology 580 
of untreated and simvastatin treated cells (5, 10 µM, 96 hours) in 3D culture. (C-H). Viability 581 
assay was done by adding the live/dead solution to cells 48 and 96 hours after treatment with 582 
simvastatin (0–20 µM). Cells were incubated for 2 hours in the dark at room temperature, rinsed 583 
three times with DPBS, and confocal microscopy was used to capture live/dead cell images in 584 
C2C12 (C) and RH30 (D) cells. Quantification of live/dead assay was measured by calculating 585 
the ratio of live: total cells which showed a significant decrease in viability of C2C12 (E&F) and 586 
RH30 (G&H) cells treated with different concentrations of simvastatin. The data showed 587 
simvastatin significantly induces cell death in both C2C12 and RH30 cells (P < 0.0001) while 588 
simvastatin induces more cell death in RH30 compared to C2C12 cells. (I&J) IF labeling of 589 
C2C12 cells (I) and RH30 cells (J) by cleaved PARP following treatment with simvastatin 590 
(10 µM, 48 hours) increased number of cells with cleaved PARP in simvastatin treated cells in 591 
comparison to control cells which is the hallmark of increase of apoptosis in these cells. (K&L) 592 
After treatment of C2C12 (K) and RH30 (L) cells with simvastatin (10 µM, 48 h), cells were IF 593 
labeled with autophagosome markers, LC3 and P62. Data showed that simvastatin increases LC3 594 
puncta (green) which is not localized with p62 compared to corresponding time-matched control, 595 
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